Interpulmonary fibrosis is a chronic, aggravated lung disease that is treated in multiple ways. The treatment of inter-pulmonary fibrosis is described below:
I. Diagnosis
Clinical performance
Patients with inter-pulmonary fibrosis are usually shown to experience increased respiratory difficulties, especially labour-related respiratory difficulties, and may be associated with such symptoms as cough, cough (mostly dry cough or a small amount of white slime).
As the condition evolves, the patient may suffer from systemic symptoms such as wasting, inactivity, appetite, arthritis, etc.
Auxiliary examination
Video-screening: The chest X-rays may show an increase in the density of the double-down pulmonary field, such as grinding glass samples, which, as the disease progresses, may result in linear strip textures, which can be described as a fine grid sample, known as a web image. High-resolution CT (HRCT) examinations can show irregular linear changes, accompanied by a cystic small aerobic cavity.
Pulmonary function examination: A decrease in restricted aerobic disorders and dispersive functions is commonly shown.
Bneumatic irradiation: assistance in obtaining information on pneumonia and fibrosis.
Visibility: For patients suspected of inter-pulmonary fibrosis, it may be necessary to clearly diagnose them through biopsy.
Diagnostic criteria
Surgery shows a change in ISP.
Discontinuation of diseases known to cause mesogenic pulmonary disease, such as drug poisoning.
Pulmonary function check-ups are unusual, as demonstrated by the reduction of pulmonary restricted ventilation or dispersive functions.
Regular X-rays or high-resolution CTs show a grid or beehive lung, respectively, for both lower and lower lungs, with small changes in hair glass.
They are older than 50 years of age, are in hiding, have a pathology of more than three months, and are heard and inhaled in the velcro-breath sound.
Treatment
Drug treatment
Common drugs include thiphonone, Nidanib, etc., which slows progress.
Sugar cortex hormonals, such as Pennison, are also commonly used for the treatment of inter-pulmonary fibrosis, especially during disease activity. It needs to be noted, however, that the long-term use of sugar cortex hormones can lead to a range of side effects, such as osteoporosis, increased blood sugar, etc.
Immunosuppressants such as cyclophosphate may be effective in some specific types of inter-pulmonary fibrosis.
Oxygen.
For patients with aerobic deficiencies, oxygen use improves the oxygen cortex and improves the quality of life. Late patients may need long-term oxygen therapy.
Lung rehabilitation
These include respiratory training, physical training, etc., which helps to improve the respiratory function and physical strength and improve the quality of life of patients.
Lung transplant
Pulmonary transplants may be an effective treatment for patients with severe medical conditions and ineffective medication. However, pulmonary transplants are at high risk and need to be found for suitable supply.
III. PROGRESS AND FOLLOW-UP
Advance
The prognosis of interpulmonary fibrosis varies according to the individual. In general, early diagnosis and active treatment can slow progress and improve the quality of life of patients. However, some patients may suffer severe damage to their lung function, or even life-threatening, as a result of serious illness or late treatment.
Follow-up visits
Patients with inter-pulmonary fibrosis require regular follow-up visits, including visual examinations, lung function checks, etc., to assess changes in the condition and the effectiveness of treatment. Doctors adjust the treatment to follow-up results to ensure that patients receive the best treatment.
In the light of the above, the treatment of inter-pulmonary fibrosis needs to take into account the clinical performance of patients, the results of supplementary examinations and the individual situation. Early diagnosis and active treatment can slow progress and improve the quality of life of patients. At the same time, patients are required to actively cooperate with the doctor ‘ s recommendations for treatment, and to conduct regular follow-up and management.
